Skip to main content
Clinical Trials/DRKS00008974
DRKS00008974
Completed
N/A

Individualized short-term therapy for adolescents impaired by ADHD despite previous routine care treatment (ESCAdol) - a randomized controlled trial within the consortium ‘ESCAlife’ - ESCAadol

niversitätsklinikum Würzburg0 sites157 target enrollmentDecember 28, 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Attention deficit-/hyperactivity disorder (ADHD)
Sponsor
niversitätsklinikum Würzburg
Enrollment
157
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 28, 2015
End Date
February 2, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversitätsklinikum Würzburg

Eligibility Criteria

Inclusion Criteria

  • ADHD according to DSM\-5 criteria; diagnosis established by clinician\-rated ADHD\-Checklist (DCL\-ADHS)
  • \- patient has been in ADHD routine care for a minimum of 6 months
  • \-no sufficient benefit from previous interventions developed for the treatment of ADHD children or ADHD adults (insufficient benefit defined as significant impairment by ADHD and/or co\-morbid symptoms: CGI\-S \> 4\)
  • \- patients and primary caregiver speak sufficient German

Exclusion Criteria

  • \- IQ \< 80
  • \- comorbidity: pervasive developmental disorder, schizophrenia, bipolar disorder, severe depressive episode
  • \- need for inpatient treatment
  • \- after TAU\-Phase co\-treatment including: a) intensive psychotherapies on a biweekly or more intense basis or b) medication which is not constant or not licensed for the treatment of ADHD and co\-morbid conditions

Outcomes

Primary Outcomes

Not specified

Similar Trials